# APEX1 Polymorphisms and Neuroblastoma Risk in Chinese Children: A Three-Center Case-Control Study

Authors: Jiabin Liu; Wei Jia; Rui-Xi Hua; Jinhong Zhu; Jiao Zhang; Tianyou Yang; Peng Li; Huimin Xia; Jing He; Jiwen Cheng
Journal: Oxidative Medicine and Cellular Longevity
 (2019)

---

## Abstract

Neuroblastoma is a life-threatening extracranial solid tumor, preferentially occurring in children. However, its etiology remains unclear.APEX1 is a critical gene in the base excision repair (BER) system responsible for maintaining genome stability. Given the potential effects of APEX1 polymorphisms on the ability of the DNA damage repair, many studies have investigated the association between these variants and susceptibility to several types of cancer but not neuroblastoma. Here, we conducted a three-center case-control study to evaluate the association between APEX1 polymorphisms (rs1130409 T>G, rs1760944 T>G, and rs3136817 T>C) and neuroblastoma risk in Chinese children, consisting of 469 cases and 998 controls. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated to evaluate the associations. No significant association with neuroblastoma risk was found for the studied APEX1 polymorphisms in the single locus or combination analysis. Interestingly, stratified analysis showed that rs1130409 GG genotype significantly reduced the risk of tumor in males. Furthermore, we found that carriers with 1-3 protective genotypes had a lower neuroblastoma risk in the children older than18 months and male, when compared to those without protective genotypes. In summary, our data indicate that APEX1 gene polymorphisms may have a weak effect on neuroblastoma susceptibility. These findings should be further validated by well-designed studies with larger sample size.


---

## Body

## 1. Introduction

Neuroblastoma is the most frequently diagnosed extracranial pediatric malignancy in children younger than 12 months, which accounts for almost 10% of all pediatric malignancies and 15% of pediatric cancer-related deaths [1]. Neuroblastoma is a highly heterogeneous tumor with a wide range of clinical symptoms. For instance, some patients with innocent tumors have spontaneous regression, while others have poor prognosis even after receiving intensive treatment because of the distant metastasis [2]. Overall, neuroblastoma can be classified into low-, intermediate-, and high-risk groups depending on the clinical feature, pathological phenotypes, and prognostic factors [3]. Despite the great progresses made in multimode treatments for neuroblastoma, the survival rate remains unsatisfying. The overall 5-year survival rate is around 70%; however, the survival rate for high-risk patients is lower than 40% [4]. This poor prognosis may be partially attributed to widespread metastasis at the time of diagnosis [5].Familial neuroblastoma with driver germline mutation is rare, accounting for approximately 1-2% of all cases [6]. The genetic alterations in the PHOX2B and ALK genes play an important role in familial neuroblastoma [7, 8]. However, the genetic mechanism of the sporadic neuroblastoma is poorly understood. Some environmental factors have been proposed as potential risk factors, such as maternal medication use, dwelling condition, childhood infections, conception, and pregnancy exposures [9, 10]. To date, a direct link between neuroblastoma and environmental factors is still missing. Excitingly, the progresses in the understanding of human genome and genotyping technologies have made the genome-wide association study (GWAS) a powerful tool to study inherited genetic variations, which are associated with complex human diseases (e.g., cancer) [11]. The first neuroblastoma GWAS was performed by Maris et al. in 2008. They found that CASC15 gene polymorphisms were significantly related to neuroblastoma susceptibility [12]. Later on, the same group reported that common variants in BARD1 gene were associated with high-risk neuroblastoma [13], and polymorphisms within DUSP12, DDX4, IL31RA, and HSD17B12 were associated with low-risk neuroblastoma [14]. In 2011, Wang et al. demonstrated that LMO1 gene polymorphisms could alter the neuroblastoma susceptibility [15]. Diskin et al. proved that polymorphisms in LIN28B and HACE1 genes were also able to alter susceptibility to neuroblastoma [16]. Furthermore, the association of the polymorphisms in TP53 [17] and MMP20 [18] genes with the neuroblastoma risk was also discovered by recent GWASs successively. In addition, candidate gene approaches have been useful in identifying potential variants associated with neuroblastoma. For instance, Capasso et al. found that common variants in NEFL were associated with neuroblastoma susceptibility with 2101 neuroblastoma cases and 4202 controls of Caucasian ancestry as well as 459 neuroblastoma patients and 809 cancer-free controls of Italian descent [19]. They also discover a functional variant in the CDKN1B gene modifying neuroblastoma susceptibility [20]. Moreover, several other predisposing genes including BARD1 [21], FAS and FASL [22], XPG [23], HOTAIR [24], and ERCC1/XPF [25] have been discovered through candidate gene approaches.The human genome continuously suffers from DNA damages caused by exogenous (e.g., ultraviolet light, ionizing radiation chemicals) and endogenous (intracellular hydrolysis and metabolic by-products) factors. For example, the reactive oxygen species can give rise to oxidant-induced base lesions [26], which may eventually lead to genomic instability and increase tumor susceptibility if not repaired accurately. Hence, the DNA repair systems play important roles in maintaining the genomic integrity and cellular normal physiological function [27].Base excision repair (BER) is one of the most important repair mechanisms for DNA lesions. It is widely accepted that BER is the primary pathway for repairing numerous oxidized and alkylated bases [28]. BER maintains genome integrity through recognition and excision of damaged bases. The protein product of the apurinic/apyrimidinic endonuclease 1 (APEX1) gene is one of critical enzymes in this DNA repair pathway [29]. It is reasonable to speculate that functional single nucleotide polymorphisms (SNPs) in APEX1 may affect DNA repair ability by affecting expression or function of the gene, which may further cause cell dysfunction, mutagenesis, and eventually tumorigenesis [30]. APEX1 gene polymorphisms have been shown to associate with colorectal cancer [31], cervical cancer [32], and ovarian cancer [33]. However, no publications have reported the associations of APEX1 gene polymorphisms with neuroblastoma risk. Therefore, we performed this three-center case-control study to assess such association in Chinese children.


## 2. Materials and Methods

### 2.1. Study Population

In the current three-center case-control research, a total of 469 histopathologically diagnosed neuroblastoma cases and 998 cancer-free controls of Chinese origin were recruited (Supplemental Table1). Among them, 275 cases and 531 controls were recruited from Guangzhou [34–37], 118 cases and 281 controls from Zhengzhou [38–40], and the remaining 76 cases and 281 controls from Xi’an [41]. Informed consent was signed by the parents or guardians of all participants. The research protocol was authorized by the institutional review boards of corresponding institutions.


### 2.2. Polymorphism Selection and Genotyping

Potential functional polymorphisms in theAPEX1 gene were identified through the dbSNP database (http://www.ncbi.nlm.nih.gov/) and SNPinfo (http://snpinfo.niehs.nih.gov/) [42]. Briefly, we searched the SNPs located in the untranslated regions, two terminals, and exon of the APEX1 gene. Additional selection criteria were referred from our previous publication [43]. Three SNPs (rs1130409 T>G, rs1760944 T>G, and rs3136817 T>C) in the APEX1 gene were eventually selected. As shown in Supplemental Figure 1, there is no significant linkage disequilibrium (R2<0.8) among these three included SNPs for Chinese Han subjects (R2=0.130 between rs1760944 and rs3136817, R2=0.076 between rs1760944 and rs1130409, and R2=0.131 between rs3136817 and rs1130409). Genomic DNA was extracted from venous blood of participants applying the TIANamp Blood DNA Kit (TIANGEN Biotech Co. Ltd., Beijing, China). Then, the purified DNA samples were genotyped for the selected polymorphisms by the standard TaqMan real-time PCR [44–47]. To ensure the reliability of the results, 10% of the DNA samples were chosen randomly for a second-time genotyping. All duplicate samples receive a concordance rate of 100%.


### 2.3. Statistical Analysis

Deviation from the Hardy-Weinberg equilibrium (HWE) for the selected SNPs in all controls was checked by a goodness-of-fitχ2 test. A two-sided chi-square test was used to compare distributions of demographics and allele frequencies between all cases and controls. By unconditional logistic regression analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for assessing the association between APEX1 polymorphisms and neuroblastoma risk. Furthermore, we conducted stratified analysis according to age, gender, tumor origin site, and clinical stage. All statistical analyses were performed by applying version 9.4 SAS software (SAS Institute, NC, USA). The P values < 0.05 were thought to be statistically significant.


## 2.1. Study Population

In the current three-center case-control research, a total of 469 histopathologically diagnosed neuroblastoma cases and 998 cancer-free controls of Chinese origin were recruited (Supplemental Table1). Among them, 275 cases and 531 controls were recruited from Guangzhou [34–37], 118 cases and 281 controls from Zhengzhou [38–40], and the remaining 76 cases and 281 controls from Xi’an [41]. Informed consent was signed by the parents or guardians of all participants. The research protocol was authorized by the institutional review boards of corresponding institutions.


## 2.2. Polymorphism Selection and Genotyping

Potential functional polymorphisms in theAPEX1 gene were identified through the dbSNP database (http://www.ncbi.nlm.nih.gov/) and SNPinfo (http://snpinfo.niehs.nih.gov/) [42]. Briefly, we searched the SNPs located in the untranslated regions, two terminals, and exon of the APEX1 gene. Additional selection criteria were referred from our previous publication [43]. Three SNPs (rs1130409 T>G, rs1760944 T>G, and rs3136817 T>C) in the APEX1 gene were eventually selected. As shown in Supplemental Figure 1, there is no significant linkage disequilibrium (R2<0.8) among these three included SNPs for Chinese Han subjects (R2=0.130 between rs1760944 and rs3136817, R2=0.076 between rs1760944 and rs1130409, and R2=0.131 between rs3136817 and rs1130409). Genomic DNA was extracted from venous blood of participants applying the TIANamp Blood DNA Kit (TIANGEN Biotech Co. Ltd., Beijing, China). Then, the purified DNA samples were genotyped for the selected polymorphisms by the standard TaqMan real-time PCR [44–47]. To ensure the reliability of the results, 10% of the DNA samples were chosen randomly for a second-time genotyping. All duplicate samples receive a concordance rate of 100%.


## 2.3. Statistical Analysis

Deviation from the Hardy-Weinberg equilibrium (HWE) for the selected SNPs in all controls was checked by a goodness-of-fitχ2 test. A two-sided chi-square test was used to compare distributions of demographics and allele frequencies between all cases and controls. By unconditional logistic regression analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for assessing the association between APEX1 polymorphisms and neuroblastoma risk. Furthermore, we conducted stratified analysis according to age, gender, tumor origin site, and clinical stage. All statistical analyses were performed by applying version 9.4 SAS software (SAS Institute, NC, USA). The P values < 0.05 were thought to be statistically significant.


## 3. Results

### 3.1. Associations betweenAPEX1 Polymorphisms and Neuroblastoma Risk

In general, this three-center case-control study contains 469 cases and 998 controls, of which genotyping was successfully performed in 469 cases and 997 controls. As shown in Table1, the observed genotype frequencies of the three polymorphisms are consistent with HWE in control subjects (rs1130409: HWE=0.190, rs1760944: HWE=0.231, and rs3136817: HWE=0.783). Unfortunately, after adjusting for age and gender, we failed to find significant association between the selected APEX1 polymorphisms and neuroblastoma risk in the single locus analysis among combined subjects (Table 1) and among subjects from each center (Supplemental Table 2). We further assessed the combined effect of protective polymorphisms of APEX1 gene on neuroblastoma risk. Subjects carrying 1-3 combined protective genotypes of APEX1 have a lower risk of neuroblastoma when compared with those without a protective genotype, though not statistically significant (adjustedOR=0.81, 95%CI=0.64‐1.01, P=0.064) (Table 1).Table 1
Association betweenAPEX1 gene polymorphisms and neuroblastoma risk.
Genotype
Cases (N=469)
Controls (N=997)a
Pb
Crude OR (95% CI)
P
Adjusted OR (95% CI)c
Pc
rs1130409 (HWE=0.190)
TT
175 (37.31)
340 (34.10)
1.00
1.00
TG
216 (46.06)
467 (46.84)
0.90 (0.70-1.15)
0.389
0.90 (0.70-1.15)
0.390
GG
78 (16.63)
190 (19.06)
0.80 (0.58-1.10)
0.167
0.79 (0.58-1.09)
0.159
Additive
0.367
0.89 (0.77-1.04)
0.157
0.89 (0.76-1.04)
0.151
Dominant
294 (62.69)
657 (65.90)
0.230
0.87 (0.69-1.09)
0.230
0.87 (0.69-1.09)
0.226
Recessive
391 (83.37)
807 (80.94)
0.262
0.85 (0.63-1.13)
0.263
0.84 (0.63-1.13)
0.250
rs1760944 (HWE=0.231)
TT
155 (33.05)
334 (33.50)
1.00
1.00
TG
230 (49.04)
470 (47.14)
1.05 (0.82-1.35)
0.674
1.06 (0.83-1.35)
0.665
GG
84 (17.91)
193 (19.36)
0.94 (0.68-1.29)
0.694
0.94 (0.68-1.29)
0.700
Additive
0.736
0.98 (0.84-1.15)
0.802
0.98 (0.84-1.15)
0.810
Dominant
314 (66.95)
663 (66.50)
0.864
1.02 (0.81-1.29)
0.864
1.02 (0.81-1.29)
0.854
Recessive
385 (82.09)
804 (80.64)
0.509
0.91 (0.69-1.21)
0.509
0.91 (0.69-1.21)
0.511
rs3136817 (HWE=0.783)
TT
396 (84.43)
815 (81.75)
1.00
1.00
TC
67 (14.29)
172 (17.25)
0.80 (0.59-1.09)
0.158
0.80 (0.59-1.09)
0.163
CC
6 (1.28)
10 (1.00)
1.24 (0.45-3.42)
0.685
1.23 (0.44-3.41)
0.692
Additive
0.329
0.87 (0.66-1.14)
0.300
0.87 (0.66-1.14)
0.306
Dominant
73 (15.57)
182 (18.25)
0.205
0.83 (0.61-1.11)
0.206
0.83 (0.62-1.11)
0.211
Recessive
463 (98.72)
987 (99.00)
0.635
1.28 (0.46-3.54)
0.636
1.27 (0.46-3.52)
0.644
Combined effect of protective genotypesd
0
305 (65.03)
598 (59.98)
1.00
1.00
1-3
164 (34.97)
399 (40.02)
0.064
0.81 (0.64-1.01)
0.064
0.81 (0.64-1.01)
0.064
OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium.aOne was failed in genotyping. bThe χ2 test for genotype distributions between neuroblastoma patients and cancer-free controls. cAdjusted for age and gender. dProtective genotypes were rs1130409 GG, rs1760944 GG, and rs3136817 TC/TT.


### 3.2. Stratification Analysis

To evaluate the effects of selectedAPEX1 polymorphisms on neuroblastoma risk among different subgroups, stratified analysis was conducted based on the age, gender, site of tumor origin, and clinical stage (Table 2). Null correlations were found between two polymorphisms (rs1760944 T>G and rs3136817 T>C) and neuroblastoma risk. Interestingly, we detected that subjects with rs1130409 GG genotype have significantly decreased neuroblastoma risk in the male subgroup (adjustedOR=0.67, 95%CI=0.44‐0.995, P=0.047) compared with the reference group. To assess the cumulative effects of protective genotypes among subgroups, we further performed a combined analysis. Results show that subjects harboring 1-3 protective genotypes had a significantly reduced neuroblastoma risk in the following subgroups: age>18 months (adjustedOR=0.70, 95%=0.52‐0.94, P=0.016) and males (adjustedOR=0.64, 95%CI=0.47‐0.87, P=0.005).Table 2
Stratification analysis for association betweenAPEX1 gene genotypes and neuroblastoma susceptibility.
Variables
rs1130409 (case/control)
AOR (95% CI)a
Pa
rs1760944 (case/control)
AOR (95% CI)a
Pa
rs3136817 (case/control)
AOR (95% CI)a
Pa
Protective genotypes (case/control)
AOR (95% CI)a
Pa
TT/TG
GG
TT/TG
GG
TT
TC/CC
0
1-3
Age (month)
≤18
138/319
31/71
1.01 (0.64-1.62)
0.958
135/314
34/76
1.04 (0.66-1.63)
0.874
139/325
30/65
1.09 (0.68-1.75)
0.733
101/234
68/156
1.01 (0.70-1.46)
0.949
>18
253/488
47/119
0.76 (0.52-1.09)
0.137
250/490
50/117
0.84 (0.58-1.21)
0.344
257/490
43/117
0.70 (0.48-1.02)
0.066
204/364
96/243
0.70 (0.52-0.94)
0.016
Gender
Female
155/335
41/79
1.12 (0.73-1.71)
0.602
161/336
35/78
0.94 (0.60-1.46)
0.776
162/238
34/76
0.93 (0.60-1.46)
0.763
114/249
82/165
1.09 (0.77-1.53)
0.643
Male
236/472
37/111
0.67 (0.44-0.995)
0.047
224/468
49/115
0.89 (0.61-1.29)
0.527
234/477
39/106
0.75 (0.51-1.12)
0.166
191/349
82/234
0.64 (0.47-0.87)
0.005
Sites of origin
Adrenal gland
136/807
26/190
0.80 (0.51-1.25)
0.323
134/804
28/193
0.87 (0.56-1.34)
0.521
137/815
25/182
0.83 (0.53-1.31)
0.430
108/598
54/399
0.75 (0.53-1.07)
0.111
Retroperitoneal
114/807
24/190
0.90 (0.56-1.44)
0.661
113/804
25/193
0.92 (0.58-1.45)
0.710
119/815
19/182
0.71 (0.43-1.18)
0.189
87/598
51/399
0.88 (0.61-1.27)
0.485
Mediastinum
101/807
20/190
0.85 (0.51-1.40)
0.516
100/804
21/193
0.88 (0.53-1.44)
0.603
101/815
20/182
0.88 (0.53-1.47)
0.633
80/598
41/399
0.77 (0.51-1.14)
0.187
Others
33/807
7/190
0.91 (0.40-2.09)
0.822
30/804
10/193
1.38 (0.66-2.88)
0.388
31/815
9/182
1.29 (0.61-2.76)
0.508
23/598
17/399
1.10 (0.58-2.09)
0.763
Clinical stage
I+II+4s
192/807
41/190
0.91 (0.63-1.32)
0.607
192/804
41/193
0.89 (0.61-1.29)
0.523
197/815
36/182
0.81 (0.55-1.19)
0.283
148/598
85/399
0.85 (0.64-1.15)
0.293
III+IV
179/807
37/190
0.86 (0.58-1.27)
0.436
176/804
40/193
0.94 (0.64-1.37)
0.747
183/815
33/182
0.81 (0.54-1.22)
0.321
143/598
73/399
0.76 (0.56-1.04)
0.088
AOR: adjusted odds ratio; CI: confidence interval.aAdjusted for age and gender, omitting the corresponding stratify factor.


## 3.1. Associations betweenAPEX1 Polymorphisms and Neuroblastoma Risk

In general, this three-center case-control study contains 469 cases and 998 controls, of which genotyping was successfully performed in 469 cases and 997 controls. As shown in Table1, the observed genotype frequencies of the three polymorphisms are consistent with HWE in control subjects (rs1130409: HWE=0.190, rs1760944: HWE=0.231, and rs3136817: HWE=0.783). Unfortunately, after adjusting for age and gender, we failed to find significant association between the selected APEX1 polymorphisms and neuroblastoma risk in the single locus analysis among combined subjects (Table 1) and among subjects from each center (Supplemental Table 2). We further assessed the combined effect of protective polymorphisms of APEX1 gene on neuroblastoma risk. Subjects carrying 1-3 combined protective genotypes of APEX1 have a lower risk of neuroblastoma when compared with those without a protective genotype, though not statistically significant (adjustedOR=0.81, 95%CI=0.64‐1.01, P=0.064) (Table 1).Table 1
Association betweenAPEX1 gene polymorphisms and neuroblastoma risk.
Genotype
Cases (N=469)
Controls (N=997)a
Pb
Crude OR (95% CI)
P
Adjusted OR (95% CI)c
Pc
rs1130409 (HWE=0.190)
TT
175 (37.31)
340 (34.10)
1.00
1.00
TG
216 (46.06)
467 (46.84)
0.90 (0.70-1.15)
0.389
0.90 (0.70-1.15)
0.390
GG
78 (16.63)
190 (19.06)
0.80 (0.58-1.10)
0.167
0.79 (0.58-1.09)
0.159
Additive
0.367
0.89 (0.77-1.04)
0.157
0.89 (0.76-1.04)
0.151
Dominant
294 (62.69)
657 (65.90)
0.230
0.87 (0.69-1.09)
0.230
0.87 (0.69-1.09)
0.226
Recessive
391 (83.37)
807 (80.94)
0.262
0.85 (0.63-1.13)
0.263
0.84 (0.63-1.13)
0.250
rs1760944 (HWE=0.231)
TT
155 (33.05)
334 (33.50)
1.00
1.00
TG
230 (49.04)
470 (47.14)
1.05 (0.82-1.35)
0.674
1.06 (0.83-1.35)
0.665
GG
84 (17.91)
193 (19.36)
0.94 (0.68-1.29)
0.694
0.94 (0.68-1.29)
0.700
Additive
0.736
0.98 (0.84-1.15)
0.802
0.98 (0.84-1.15)
0.810
Dominant
314 (66.95)
663 (66.50)
0.864
1.02 (0.81-1.29)
0.864
1.02 (0.81-1.29)
0.854
Recessive
385 (82.09)
804 (80.64)
0.509
0.91 (0.69-1.21)
0.509
0.91 (0.69-1.21)
0.511
rs3136817 (HWE=0.783)
TT
396 (84.43)
815 (81.75)
1.00
1.00
TC
67 (14.29)
172 (17.25)
0.80 (0.59-1.09)
0.158
0.80 (0.59-1.09)
0.163
CC
6 (1.28)
10 (1.00)
1.24 (0.45-3.42)
0.685
1.23 (0.44-3.41)
0.692
Additive
0.329
0.87 (0.66-1.14)
0.300
0.87 (0.66-1.14)
0.306
Dominant
73 (15.57)
182 (18.25)
0.205
0.83 (0.61-1.11)
0.206
0.83 (0.62-1.11)
0.211
Recessive
463 (98.72)
987 (99.00)
0.635
1.28 (0.46-3.54)
0.636
1.27 (0.46-3.52)
0.644
Combined effect of protective genotypesd
0
305 (65.03)
598 (59.98)
1.00
1.00
1-3
164 (34.97)
399 (40.02)
0.064
0.81 (0.64-1.01)
0.064
0.81 (0.64-1.01)
0.064
OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium.aOne was failed in genotyping. bThe χ2 test for genotype distributions between neuroblastoma patients and cancer-free controls. cAdjusted for age and gender. dProtective genotypes were rs1130409 GG, rs1760944 GG, and rs3136817 TC/TT.


## 3.2. Stratification Analysis

To evaluate the effects of selectedAPEX1 polymorphisms on neuroblastoma risk among different subgroups, stratified analysis was conducted based on the age, gender, site of tumor origin, and clinical stage (Table 2). Null correlations were found between two polymorphisms (rs1760944 T>G and rs3136817 T>C) and neuroblastoma risk. Interestingly, we detected that subjects with rs1130409 GG genotype have significantly decreased neuroblastoma risk in the male subgroup (adjustedOR=0.67, 95%CI=0.44‐0.995, P=0.047) compared with the reference group. To assess the cumulative effects of protective genotypes among subgroups, we further performed a combined analysis. Results show that subjects harboring 1-3 protective genotypes had a significantly reduced neuroblastoma risk in the following subgroups: age>18 months (adjustedOR=0.70, 95%=0.52‐0.94, P=0.016) and males (adjustedOR=0.64, 95%CI=0.47‐0.87, P=0.005).Table 2
Stratification analysis for association betweenAPEX1 gene genotypes and neuroblastoma susceptibility.
Variables
rs1130409 (case/control)
AOR (95% CI)a
Pa
rs1760944 (case/control)
AOR (95% CI)a
Pa
rs3136817 (case/control)
AOR (95% CI)a
Pa
Protective genotypes (case/control)
AOR (95% CI)a
Pa
TT/TG
GG
TT/TG
GG
TT
TC/CC
0
1-3
Age (month)
≤18
138/319
31/71
1.01 (0.64-1.62)
0.958
135/314
34/76
1.04 (0.66-1.63)
0.874
139/325
30/65
1.09 (0.68-1.75)
0.733
101/234
68/156
1.01 (0.70-1.46)
0.949
>18
253/488
47/119
0.76 (0.52-1.09)
0.137
250/490
50/117
0.84 (0.58-1.21)
0.344
257/490
43/117
0.70 (0.48-1.02)
0.066
204/364
96/243
0.70 (0.52-0.94)
0.016
Gender
Female
155/335
41/79
1.12 (0.73-1.71)
0.602
161/336
35/78
0.94 (0.60-1.46)
0.776
162/238
34/76
0.93 (0.60-1.46)
0.763
114/249
82/165
1.09 (0.77-1.53)
0.643
Male
236/472
37/111
0.67 (0.44-0.995)
0.047
224/468
49/115
0.89 (0.61-1.29)
0.527
234/477
39/106
0.75 (0.51-1.12)
0.166
191/349
82/234
0.64 (0.47-0.87)
0.005
Sites of origin
Adrenal gland
136/807
26/190
0.80 (0.51-1.25)
0.323
134/804
28/193
0.87 (0.56-1.34)
0.521
137/815
25/182
0.83 (0.53-1.31)
0.430
108/598
54/399
0.75 (0.53-1.07)
0.111
Retroperitoneal
114/807
24/190
0.90 (0.56-1.44)
0.661
113/804
25/193
0.92 (0.58-1.45)
0.710
119/815
19/182
0.71 (0.43-1.18)
0.189
87/598
51/399
0.88 (0.61-1.27)
0.485
Mediastinum
101/807
20/190
0.85 (0.51-1.40)
0.516
100/804
21/193
0.88 (0.53-1.44)
0.603
101/815
20/182
0.88 (0.53-1.47)
0.633
80/598
41/399
0.77 (0.51-1.14)
0.187
Others
33/807
7/190
0.91 (0.40-2.09)
0.822
30/804
10/193
1.38 (0.66-2.88)
0.388
31/815
9/182
1.29 (0.61-2.76)
0.508
23/598
17/399
1.10 (0.58-2.09)
0.763
Clinical stage
I+II+4s
192/807
41/190
0.91 (0.63-1.32)
0.607
192/804
41/193
0.89 (0.61-1.29)
0.523
197/815
36/182
0.81 (0.55-1.19)
0.283
148/598
85/399
0.85 (0.64-1.15)
0.293
III+IV
179/807
37/190
0.86 (0.58-1.27)
0.436
176/804
40/193
0.94 (0.64-1.37)
0.747
183/815
33/182
0.81 (0.54-1.22)
0.321
143/598
73/399
0.76 (0.56-1.04)
0.088
AOR: adjusted odds ratio; CI: confidence interval.aAdjusted for age and gender, omitting the corresponding stratify factor.


## 4. Discussion

With an aim to investigate the effect ofAPEX1 gene polymorphisms on neuroblastoma risk, we performed this current three-center case-control study in Chinese population. Neither rs1760944 T>G nor rs3136817T>C significantly modified neuroblastoma susceptibility. However, it is noteworthy that rs1130409 GG genotype was significantly associated with reduced neuroblastoma risk in the male subgroup.TheAPEX1 gene is mapped to chromosome 14q11.2-q12 and comprises five exons and four introns with 2.21 kb length. It encodes a nuclease acting as a rate-limiting enzyme in the BER pathway [48]. When exposed to endogenous and exogenous mutagens, apurinic/apyrimidinic (AP) sites are produced in DNA. APEX1 can hydrolyze a 5′-phosphodiester bond at the AP site, thereby protecting cells against the accumulation of AP sites in DNA [49]. In addition, APEX1 can act as 3′-phosphodiesterase which could hydrolyze 3′-blocking fragments of oxidized DNA, thus producing normal nucleotide 3′-droxyl terminals. These ends are requisite for DNA repair synthesis and ligation of gaps generated from single- or double-strand breaks [50, 51]. APEX1 is endonuclease and phosphodiesterase in the BER pathway. Polymorphisms in the APEX1 gene may alter gene expression so as to affect the activity of DNA repair and the accumulation of damaged DNA, eventually leading to carcinogenesis.Variants in theAPEX1 gene are found to associate with susceptibility to several cancers, including cervical cancer [32], glioblastoma [52], bladder cancer [53], and lung cancer [49, 54]. To date, many SNPs in the APEX1 gene have been identified [55]. Among them, polymorphisms rs1130409 T>G and rs1760944 T>G were extensively studied. Polymorphism rs1130409 T>G in the fifth exon leads to Asp148Glu residue transition in the carboxy-terminus but has no direct effect on DNA-binding and endonuclease activities of APEX1. However, polymorphism rs1760944 T>G in the promoter region may be a pathogenic SNP associated with cancer risk [54]. The rs1130409 has been widely explored in a wide spectrum of cancers, such as bladder cancer [53]. De Ruyck et al. suggested that rs1130409 T>G increased lung cancer risk in Caucasians [56], but Deng et al. found that this polymorphism reduced the susceptibility to lung cancer in Asians [57]. The rs1760944 T>G, one of the most frequently investigated SNPs in the APEX1 gene, is also related to cancer susceptibility, such as nasopharyngeal carcinoma (NPC) [55] and glioblastoma [52]. Lo et al. suggested that patients with genotype rs1760944 GT or GG had lower lung cancer risk compared with those with rs1760944 TT [49]. One study performed by Kang et al. showed that the genotype of rs1760944 GG or GT may act as a protective genotype for breast cancer [58]. Li et al. found that genotype rs1760944 GG was associated with reduced risk of NPC compared with other genotypes, but the results did not reach statistical significance. More recently, one study conducted by Lu et al. confirmed that individuals with genotype rs1760944 GT or GG had significantly decreased NPC susceptibility than those with genotype rs1760944 TT [59]. These findings indicated that rs1760944 G allele may exert protective effects against several cancers. In addition, rs3136817 T>C is one of the polymorphisms in the APEX1 gene which is investigated relatively less frequently. However, there are still some reports about association between polymorphism rs3136817 T>C and cancer risk. For instance, Zhu et al. showed that rs3136817 TC genotype of the APEX1 gene was associated with lower risk of bladder cancer [60]. However, a research performed by Li et al. revealed null correlation between APEX1 rs3136817 T>C and risk of severe radiation-induced pneumonitis after radiotherapy among patients with lung cancer [61]. A recent study conducted by Wang et al. indicated that the rs3136817 TC heterozygous genotype of APEX1 has a potential protective effect for breast cancer, which may be owing to positive effect of rs3136817 TC genotype on DNA repair activity [62]. The conflicting association between APEX1 gene polymorphisms and cancer risk may be explained by the differences in the sample sizes, race, cancer types, selection criteria for subjects, and environmental exposures. Therefore, the conclusion associated between APEX1 polymorphisms and cancer risk should be specified in a particular cancer type and population.Herein, we for the first time investigated the association between theAPEX1 gene SNPs and neuroblastoma risk. No significant association was found in the single locus analysis or combined analysis. Several reasons may help to explain the unexpected negative results: (1) the role of a polymorphism in cancer susceptibility might be tissue- and ethnicity-dependent and (2) the sample size of this study was too small to detect a real association. Although no significant effect was found in the overall analysis, age and gender may modify the results. In the stratified analysis, we found that rs1130409 GG genotype significantly decreased the risk of neuroblastoma in the male subgroup. To date, the rs1130409 T>G of the APEX1 gene is the most extensively studied SNP. Moreover, we also found that the presence of 1-3 protective genotypes provided a protective effect for children>18 months of age and boys. It should be noted that these significant results may be just chance findings in the stratification analysis because of relatively small sample size.There are several accompanied limitations. First, although subjects in this current study were recruited from three independent hospitals, the sample size remains moderate, especially for the stratified analysis. As a result, the statistical powers were ineluctably whittled. Second, only three polymorphisms in theAPEX1 gene were investigated. Other potentially functional APEX1 polymorphisms should be assessed. Third, the subjects involved in this study are Chinese; therefore, the conclusions obtained from this study may not apply to other ethnicities. Fourth, only genetic analysis was performed in neuroblastoma risk. Other environmental factors such as living environment, dietary habits, and childhood or parental exposure should be considered, as neuroblastoma is a heterogeneous disease with a complicated etiology.


## 5. Conclusions

In conclusion, our present data suggest thatAPEX1 polymorphisms affect neuroblastoma susceptibility in a low-penetrance manner. Well-designed multicenter studies with larger sample size are needed to confirm our findings. Furthermore, functional validation should be performed to clarify the underlying mechanisms by which APEX1 gene polymorphisms affect neuroblastoma susceptibility.



---

*Source: 5736175-2019-06-25.xml*